News

In the single dose, single-site, randomised, placebo- and active-controlled study, 135 subjects received Vyvanse 20mg, 50mg, 70mg, placebo or the active comparator (armodafinil 250mg (NUVIGIL)). On the primary

Reportedly, the company has recruited first patient in September 2010. In the trial, the patients are expected to receive immunization over a period of six months, with the

With this, Mannatech will now hold 12 patents for technology related to Ambrotose AO in Australia, Mexico, New Zealand, Singapore, South Africa and South Korea. Mannatech co-CEO and

GSK and Galapagos signed the arthritis alliance in June 2006 for the discovery and development of disease-modifying drugs for GSK’s global R&D organization. In the trial, GLPG0555 was

The proposal combines IDRI’s vaccine-adjuvant technology and a micro-needle delivery device to create a device-adjuvant platform. The platform will have the potential for intra-dermal delivery of a variety

The idea is to gain accreditations allowing the packing of controlled drugs. Wasdell Packaging has also ordered new kits for the scanning and printing of 2D data matrixes

Resolvyx Pharma has scheduled RX-10045 Phase III randomized, placebo-controlled, multi-center study in 2011. Under the agreement, Celtic Therapeutics may also license rights to and develop a second Resolvyx

Under the agreement Hi-Tech Pharmacal will be responsible for submitting the abbreviated new drug application (ANDA) for the finished product, which will be filed under Hi-Tech Pharmacal’s name.

The company has received the US Food and Drug Administration (FDA) clearence for Prontosan Wound Management Gel for OTC use in November 2010. B Braun Medical said the